These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 11732279

  • 21. Early interneuron dysfunction in ALS: insights from a mutant sod1 zebrafish model.
    McGown A, McDearmid JR, Panagiotaki N, Tong H, Al Mashhadi S, Redhead N, Lyon AN, Beattie CE, Shaw PJ, Ramesh TM.
    Ann Neurol; 2013 Feb; 73(2):246-58. PubMed ID: 23281025
    [Abstract] [Full Text] [Related]

  • 22. Riluzole does not improve lifespan or motor function in three ALS mouse models.
    Hogg MC, Halang L, Woods I, Coughlan KS, Prehn JHM.
    Amyotroph Lateral Scler Frontotemporal Degener; 2018 Aug; 19(5-6):438-445. PubMed ID: 29221425
    [Abstract] [Full Text] [Related]

  • 23. [The advance in the research and therapeutic trials of amyotrophic lateral sclerosis].
    Moriwaka F, Tashiro K.
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1258-60. PubMed ID: 11464472
    [Abstract] [Full Text] [Related]

  • 24. Riluzole, neuroprotection and amyotrophic lateral sclerosis.
    Cheah BC, Vucic S, Krishnan AV, Kiernan MC.
    Curr Med Chem; 2010 Dec; 17(18):1942-199. PubMed ID: 20377511
    [Abstract] [Full Text] [Related]

  • 25. Three novel mutations and two variants in the gene for Cu/Zn superoxide dismutase in familial amyotrophic lateral sclerosis.
    Hosler BA, Nicholson GA, Sapp PC, Chin W, Orrell RW, de Belleroche JS, Esteban J, Hayward LJ, Mckenna-Yasek D, Yeung L, Cherryson AK, Dench JE, Wilton SD, Laing NG, Horvitz HR, Brown RH.
    Neuromuscul Disord; 1996 Oct; 6(5):361-6. PubMed ID: 8938700
    [Abstract] [Full Text] [Related]

  • 26. Riluzole for the treatment of amyotrophic lateral sclerosis.
    Saitoh Y, Takahashi Y.
    Neurodegener Dis Manag; 2020 Dec; 10(6):343-355. PubMed ID: 32847483
    [Abstract] [Full Text] [Related]

  • 27. Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis.
    Vucic S, Kiernan MC.
    Curr Mol Med; 2009 Apr; 9(3):255-72. PubMed ID: 19355908
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Activity of protein phosphatase calcineurin is decreased in sporadic and familial amyotrophic lateral sclerosispatients.
    Ferri A, Nencini M, Battistini S, Giannini F, Siciliano G, Casali C, Damiano MG, Ceroni M, Chiò A, Rotilio G, Carrì MT.
    J Neurochem; 2004 Sep; 90(5):1237-42. PubMed ID: 15312178
    [Abstract] [Full Text] [Related]

  • 31. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase.
    Kriz J, Gowing G, Julien JP.
    Ann Neurol; 2003 Apr; 53(4):429-36. PubMed ID: 12666110
    [Abstract] [Full Text] [Related]

  • 32. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis.
    Gurney ME, Fleck TJ, Himes CS, Hall ED.
    Neurology; 1998 Jan; 50(1):62-6. PubMed ID: 9443458
    [Abstract] [Full Text] [Related]

  • 33. Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.
    Noto Y, Shibuya K, Vucic S, Kiernan MC.
    Expert Rev Neurother; 2016 Oct; 16(10):1147-54. PubMed ID: 27314534
    [Abstract] [Full Text] [Related]

  • 34. [Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms].
    Kollewe K, Dengler R, Petri S.
    Nervenarzt; 2008 Jun; 79(6):653-61. PubMed ID: 18210046
    [Abstract] [Full Text] [Related]

  • 35. Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.
    Goyal NA, Mozaffar T.
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1541-51. PubMed ID: 24965719
    [Abstract] [Full Text] [Related]

  • 36. Molecular targets for neuroprotection.
    Przedborski S.
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():14-8. PubMed ID: 15512862
    [Abstract] [Full Text] [Related]

  • 37. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?
    Bellingham MC.
    CNS Neurosci Ther; 2011 Feb; 17(1):4-31. PubMed ID: 20236142
    [Abstract] [Full Text] [Related]

  • 38. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].
    Al-Chalabi A, Shaw PJ, Young CA, Morrison KE, Murphy C, Thornhill M, Kelly J, Steen IN, Leigh PN, UKMND-LiCALS.
    BMC Neurol; 2011 Sep 21; 11():111. PubMed ID: 21936930
    [Abstract] [Full Text] [Related]

  • 39. Treatment with the copper compound CuATSM has no significant effect on motor neuronal pathology in patients with ALS.
    Yang Y, Rowe D, McCann H, Shepherd CE, Kril JJ, Kiernan MC, Halliday GM, Tan RH.
    Neuropathol Appl Neurobiol; 2023 Aug 21; 49(4):e12919. PubMed ID: 37317638
    [Abstract] [Full Text] [Related]

  • 40. Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection.
    Blasco H, Patin F, Andres CR, Corcia P, Gordon PH.
    Expert Opin Pharmacother; 2016 Aug 21; 17(12):1669-82. PubMed ID: 27356036
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.